156 related articles for article (PubMed ID: 36600104)
21. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
[TBL] [Abstract][Full Text] [Related]
22. Five-Year Oncologic Outcome and Surgical Completeness of Transoral Robotic Thyroidectomy for Papillary Thyroid Carcinoma: Comparison with Conventional Transcervical Thyroidectomy Using Propensity Score Matching.
Lee SJ; Ryu SR; Ji YB; Song CM; Park JH; Kim DS; Tae K
Ann Surg Oncol; 2023 Apr; 30(4):2256-2264. PubMed ID: 36602660
[TBL] [Abstract][Full Text] [Related]
23. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
24. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
[TBL] [Abstract][Full Text] [Related]
25. Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis.
Satapathy S; Tupalli A; Chandekar KR; Ballal S; Bal C
Clin Endocrinol (Oxf); 2023 Nov; 99(5):483-491. PubMed ID: 37491776
[TBL] [Abstract][Full Text] [Related]
26. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
28. External Beam Radiotherapy for Medullary Thyroid Cancer Following Total or Near-Total Thyroidectomy.
Jin M; Megwalu UC; Noel JE
Otolaryngol Head Neck Surg; 2021 Jan; 164(1):97-103. PubMed ID: 32746731
[TBL] [Abstract][Full Text] [Related]
29. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
[TBL] [Abstract][Full Text] [Related]
30. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
[TBL] [Abstract][Full Text] [Related]
31. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk.
Grani G; Lamartina L; Alfò M; Ramundo V; Falcone R; Giacomelli L; Biffoni M; Filetti S; Durante C
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1717-e1727. PubMed ID: 33377969
[TBL] [Abstract][Full Text] [Related]
32. Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer--a randomized controlled trial.
Sawka AM; Straus S; Brierley JD; Tsang RW; Rotstein L; Rodin G; Gafni A; Ezzat S; Thabane L; Thorpe KE; Goldstein DP
Trials; 2010 Jul; 11():81. PubMed ID: 20659341
[TBL] [Abstract][Full Text] [Related]
33. External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society.
Kiess AP; Agrawal N; Brierley JD; Duvvuri U; Ferris RL; Genden E; Wong RJ; Tuttle RM; Lee NY; Randolph GW
Head Neck; 2016 Apr; 38(4):493-8. PubMed ID: 26716601
[TBL] [Abstract][Full Text] [Related]
34. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
[TBL] [Abstract][Full Text] [Related]
35. The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma.
Sun W; Di L; Chen L; Li D; Wu Y; Xiang J; Zhou S; Sun T
BMC Surg; 2022 Nov; 22(1):374. PubMed ID: 36324095
[TBL] [Abstract][Full Text] [Related]
36. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
37. The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma.
Hwang H; Lee NK
Saudi Med J; 2021 Aug; 42(8):832-837. PubMed ID: 34344806
[TBL] [Abstract][Full Text] [Related]
38. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
Zhao H; Gong Y
Front Endocrinol (Lausanne); 2022; 13():960682. PubMed ID: 36034423
[TBL] [Abstract][Full Text] [Related]
39. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
Chandekar KR; Satapathy S; Bal C
Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
[TBL] [Abstract][Full Text] [Related]
40. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]